CORTROSYN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cortrosyn, and when can generic versions of Cortrosyn launch?
Cortrosyn is a drug marketed by Amphastar Pharms Inc and is included in one NDA.
The generic ingredient in CORTROSYN is cosyntropin. There are two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cosyntropin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cortrosyn
A generic version of CORTROSYN was approved as cosyntropin by MYLAN INSTITUTIONAL on December 17th, 2009.
Summary for CORTROSYN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 51 |
Clinical Trials: | 7 |
Patent Applications: | 1,378 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CORTROSYN |
What excipients (inactive ingredients) are in CORTROSYN? | CORTROSYN excipients list |
DailyMed Link: | CORTROSYN at DailyMed |
Recent Clinical Trials for CORTROSYN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) | N/A |
Vanderbilt University | N/A |
National Institutes of Health (NIH) | N/A |
Pharmacology for CORTROSYN
Drug Class | Adrenocorticotropic Hormone |
US Patents and Regulatory Information for CORTROSYN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | CORTROSYN | cosyntropin | INJECTABLE;INJECTION | 016750-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |